Investor Relations

In response to recent events, Valeant has developed an online archive of rebuttals to many of the allegations that have been made against the company.

You can find these rebuttals here

Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis

Read the full Story

34th Annual J.P. Morgan Healthcare Conference

01/13/16

View the Presentation

Valeant is a diverse and decentralized organization committed to focusing on our key stakeholders while delivering consistently high performance. Our values provide the overall direction for our company as well as the tools necessary to rise to any challenge.

Our specialty pharmaceuticals, branded generics and consumer products play a role in helping millions of people live healthier lives and providing treatment to those affected by debilitating diseases. We remain committed to improving the health and well-being of people everywhere, profitably growing our businesses, and bringing value to our shareholders.

Events and Presentations

Events and Presentations

Details on upcoming events are not yet available. View All
Annual Report

2014 Annual Report

The right products
The right philosophy.
record organic growth.

View All
Email Alerts

Email Alerts

Sign up to receive email alerts whenever Valeant Pharmaceuticals International, Inc. posts new information to the site.

Register